Analysis of Human Epidermal Growth Factor Receptor -2 Expression in Gastric Adenocarcinoma

Institution: Govt. Kilpauk Medical College, Chennai BACKGROUND: Gastric carcinoma is the fourth most common cancer in the world. It is a disease of elderly and more common in males. The poor prognosis of gastric tumour is due to late presentation, nonspecific symptoms and limitations in treatment options. An association between clinicopathological features and molecular markers would give a clue toward the relationship between them and hence provide us an extra tool to combat the high mortality. METHODS: A retrospective study was conducted in 100 patients with histopathologically proven gastric adenocarcinoma. In this study , expression of Immuno histochemical marker HER -2 in gastric adeno carcinoma was analysed and compared with various clinicopathological markers. RESULTS: Her -2 Overexpression was seen in 25% of total cases. Positivity for HER-2/Neu was present in 52% of moderately differentiated tumours, 28% of well differentiated tumours and 20% of poorly differentiated tumours CONCLUSION: Statistically significant correlation was found out between Her -2 receptor over expression and different histological grades of gastric adenocarcinoma. Her- 2 receptor over expression is more common in well and moderately differentiated tumours than poorly differentiated tumours

Flow regime mapping in gas-liquid flow in micro-channels

Experiments were conducted in a micro-channel with square cross-section with each side being 3 mm.nbsp Gas-liquid flow is employed for determining the flow patterns with water being liquid phase and nitrogen being gas phase.nbsp Over a wide range of gas and liquid velocities the flow patterns were studied using visual inspection technique.nbsp It is found that four types of flow regimes occurred within the range of variables considered in the present study.nbsp These are bubble flow, slug flow, channel flow and transient flow.nbsp A flow regime map is also constructed

A Non aqueous Formulation for Efficient Detoxification of Chemical Weapons at Sub zero Temperatures

An effective decontamination methodology based on nucleophilic non-aqueous decontaminant has been developed against chemical weapons sulfur mustard and soman. This new formulation consists of non-aqueous solution of 2-aminoethanol (60%, w/v), potassium hydroxide (2%, w/v), and N-methyl-2-pyrrolidone (38 %, w/v) and detoxified more than 99 % of sulfur mustard and soman within a period of 30 min at -35 °C. It was found to be operable over a wide range of temperatures starting from -35 °C to +55 °C without losing its fluidity and detoxicant efficiency at sub-zero temperatures promising hassle-free application against chemical weapons. It degrades sulfur mustard to divinyl sulfide and 2-chloroethyl vinyl sulfide and converted soman into O-pinacolyl O’-(2-amino) ethyl methylphosphonate, which are relatively non toxic to humans. This formulation is environmentally benign, relatively non corrosive and has an improved capability to dissolve and decontaminate chemical weapons within 15 minutes at ambient conditions. This approach paves the way for efficient and rapid decontamination platform for chemical weapons and holds considerable promise for field application in near future

Performance of bmr 6 and 12 Sorghum Mutants in Different Wild Backgrounds Under Salinity

Sorghum is one of the bioenergy crops, with considerable tolerance to salinity. The current work was undertaken to assess the salinity tolerance of brown midrib (bmr) mutant lines and wild parents for biomass composition and potential theoretical ethanol yield (TEY). The variation for salinity levels in field plots was significant; hence, salinity screening under controlled environment was performed. The mutant line N 600 (bmr-12) had performed better under field screening (at 10 dS m−1) with fresh stalk yield of 17.3 t ha−1, dry stalk yield of 7.4 t ha−1, and grain yield of 2.0 t ha−1. The performance of bmr-6 and bmr-12 mutant alleles showed that bmr-12 allele, i.e., N 597 and N 600 had performed better than its wild types EHS and Atlas, respectively, for relative fresh and dry biomass index at 20, 40 and 80 days after imposing 150 mM salinity stress. The lines N 597 (13.05 cm2 g−1), N 596 (6.84 cm2 g−1) and N 593 (7.39 cm2 g−1) recorded the highest specific leaf area at 20, 40 and 80 days of stress, respectively. High membrane stability index was recorded in mutants N 596 (bmr-6-85.33%) and N 597 (bmr-12-84.78%) with EHS though under different genetic background under stress. Higher TEY was recorded in N 597 (2219.82 L ha−1), N 600 (2159.79 L ha−1), N 595 (2019.03 L ha−1) and N 598 (1945.33 L ha−1) under stressed conditions, with a moderate reduction of 47.85 and 47.50% in 2014 and 2015, respectively, in TEY

Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience

Purpose. Neuroendocrine neoplasms (NENs) of the esophagus are very uncommon with only a few studies published worldwide. Studies on clinical profile, management, and outcomes are very uncommon. Methods. We report the largest single institution retrospective review of 43 patients of pure esophageal NENs out of our registry of gastrointestinal neuroendocrine tumors treated between 2005 and 2014. Data on the incidence, tumor location, clinical symptoms, stage at presentation, grading, treatment protocol, and treatment outcomes was collected and analyzed. Results. Among 1293 cases of esophageal cancers, pure esophageal NENs were diagnosed in 43 cases. The mean patient age was 55.8 years. The male : female ratio was 1.5 : 1. 81.4% of the tumors were located in the lower third of the esophagus and gastroesophageal junction. Neuroendocrine carcinomas (NEC; G3) accounted for the vast majority of NENs (83.7%). 53.5% patients were Stage IV and 32.5% were Stage III at presentation. The combined median survival of stages II and III patients was 18.25 months, with treatment. The median survival of treated patients with metastatic disease was 6.5 months. Conclusion. Esophageal NENs most commonly were neuroendocrine carcinomas, presented in metastatic stage and were associated with poor prognosis. Grade 2 (G2) tumors had better outcomes than NEC (G3). In nonmetastatic disease, presence of lymph node metastasis and unresectable disease had poorer outcomes

Dynamics of Hot QCD Matter -- Current Status and Developments

The discovery and characterization of hot and dense QCD matter, known as Quark Gluon Plasma (QGP), remains the most international collaborative effort and synergy between theorists and experimentalists in modern nuclear physics to date. The experimentalists around the world not only collect an unprecedented amount of data in heavy-ion collisions, at Relativistic Heavy Ion Collider (RHIC), at Brookhaven National Laboratory (BNL) in New York, USA, and the Large Hadron Collider (LHC), at CERN in Geneva, Switzerland but also analyze these data to unravel the mystery of this new phase of matter that filled a few microseconds old universe, just after the Big Bang. In the meantime, advancements in theoretical works and computing capability extend our wisdom about the hot-dense QCD matter and its dynamics through mathematical equations. The exchange of ideas between experimentalists and theoreticians is crucial for the progress of our knowledge. The motivation of this first conference named "HOT QCD Matter 2022" is to bring the community together to have a discourse on this topic. In this article, there are 36 sections discussing various topics in the field of relativistic heavy-ion collisions and related phenomena that cover a snapshot of the current experimental observations and theoretical progress. This article begins with the theoretical overview of relativistic spin-hydrodynamics in the presence of the external magnetic field, followed by the Lattice QCD results on heavy quarks in QGP, and finally, it ends with an overview of experiment results.Comment: Compilation of the contributions (148 pages) as presented in the `Hot QCD Matter 2022 conference', held from May 12 to 14, 2022, jointly organized by IIT Goa & Goa University, Goa, Indi

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)